RDC 885 Compliance Checklist: Month-by-Month Timeline Until December 2026

There are only a few months left until the RDC 885/2024 deadline, and according to informal surveys with industry associations, fewer than 20% of Brazilian pharmaceutical laboratories have begun the compliance process. If your company is among the remaining 80%, this guide offers a realistic and detailed action plan.

Phase 1: Diagnosis (Month 1-2)

Before any technical action, you need an accurate diagnosis of the current situation. This is the most neglected step and the one that causes the most delays when poorly executed.

List all medications with active ANVISA registration
For each, identify: current insert version, current format (PDF, Word, paper), date of last approved update
Classify by priority: sales volume, clinical criticality, registration renewal deadline
If you already have a portal, conduct a WCAG 2.1 AA audit with tools like axe-core, WAVE, and Lighthouse
Identify which packaging already has space for QR Codes and which will need redesign

Deliverable: Diagnostic report with complete inventory, gap analysis, and effort estimate.

Phase 2: Technology Decision (Month 2-3)

Three main paths exist: internal development (12-18 months, R$500k-2M), specialized SaaS platform (weeks to deploy, predictable cost), or a hybrid approach combining SaaS with custom API integrations.

Deliverable: Board-approved business case with selected vendor or defined development scope.

Phase 3: Content Conversion (Month 3-7)

Converting inserts from PDF to semantic, accessible HTML is not a copy-paste task. Each insert requires extraction, structuring into the 19 RDC 47/2009 sections, semantic HTML markup, regulatory review, and accessibility testing.

Estimated throughput: A trained team converts 3 to 5 inserts per day. For 100 medications, plan 4 to 6 weeks of dedicated work.

Phase 4: Technical Implementation (Month 5-8)

RIEP portal configuration, insert upload, multi-criteria search setup, TTS implementation, versioning, load testing for 99.5% uptime validation, and QR Code integration.

Phase 5: QR Codes and Packaging (Month 6-10)

QR Code inclusion in packaging is frequently the most underestimated bottleneck. Graphic suppliers typically have 4-8 week lead times. Plan this in parallel with content conversion.

Phase 6: Validation and Go-live (Month 9-11)

Complete accessibility testing (automated + manual with screen readers), usability testing with real patients, performance/load testing, regulatory validation, IQ/OQ/PQ documentation, and gradual go-live.

Phase 7: Continuous Monitoring (Month 12+)

Portal uptime monitoring, insert update process for new ANVISA-approved versions, patient feedback collection, compliance reporting, and QR Code updates for new registrations.

Common pitfalls

Underestimating content conversion: This is the most time-consuming item.
Ignoring real accessibility: Passing automated validators doesn't guarantee usability.
Leaving packaging for last: Graphic lead times are long.
Not involving legal: Version traceability has legal implications for pharmacovigilance.
Forgetting training: Customer service, medical representatives, and pharmacovigilance teams need to know the new system.